Cargando…

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series

Pseudoprogression is rarely mentioned after radiotherapy except for central nervous system tumors. With the widespread of immunotherapy, the incidence of pseudoprogression of thoracic tumor after radiotherapy is increasing. This study summarized the clinical features of pseudoprogression in 4 patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Yongbo, Tang, Wei, Wang, Jianyang, Wang, Zhijie, Bi, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419187/
https://www.ncbi.nlm.nih.gov/pubmed/37576884
http://dx.doi.org/10.3389/fonc.2023.1021253
_version_ 1785088455259193344
author Xiang, Yongbo
Tang, Wei
Wang, Jianyang
Wang, Zhijie
Bi, Nan
author_facet Xiang, Yongbo
Tang, Wei
Wang, Jianyang
Wang, Zhijie
Bi, Nan
author_sort Xiang, Yongbo
collection PubMed
description Pseudoprogression is rarely mentioned after radiotherapy except for central nervous system tumors. With the widespread of immunotherapy, the incidence of pseudoprogression of thoracic tumor after radiotherapy is increasing. This study summarized the clinical features of pseudoprogression in 4 patients who had underwent thoracic radiotherapy after and/or followed by immunotherapy. All of them had received chemotherapy and immunotherapy before thoracic radiotherapy. After radiotherapy, pseudoprogression occurred within 3 months after initiation of immune consolidation/rechallenge therapy. At least a 20% increase in the sum of the longest diameter of target lesions were measured on their chest image. During this period, patients’ ECOG PS scores remained stable, specific serum tumor markers did not increase significantly. Treatment strategies did not change after pseudoprogression. The causes of radiographic pseudoprogression in this case series may be attributed to disturbances such as pneumonitis, atelectasis, mucus blockages and infection. In the era of immunotherapy, pseudoprogression of thoracic tumors after chest radiotherapy might become a common phenomenon. It is important for us to identify pseudoprogression based on patient’s general status, radiological changes, and laboratory tests.
format Online
Article
Text
id pubmed-10419187
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104191872023-08-12 Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series Xiang, Yongbo Tang, Wei Wang, Jianyang Wang, Zhijie Bi, Nan Front Oncol Oncology Pseudoprogression is rarely mentioned after radiotherapy except for central nervous system tumors. With the widespread of immunotherapy, the incidence of pseudoprogression of thoracic tumor after radiotherapy is increasing. This study summarized the clinical features of pseudoprogression in 4 patients who had underwent thoracic radiotherapy after and/or followed by immunotherapy. All of them had received chemotherapy and immunotherapy before thoracic radiotherapy. After radiotherapy, pseudoprogression occurred within 3 months after initiation of immune consolidation/rechallenge therapy. At least a 20% increase in the sum of the longest diameter of target lesions were measured on their chest image. During this period, patients’ ECOG PS scores remained stable, specific serum tumor markers did not increase significantly. Treatment strategies did not change after pseudoprogression. The causes of radiographic pseudoprogression in this case series may be attributed to disturbances such as pneumonitis, atelectasis, mucus blockages and infection. In the era of immunotherapy, pseudoprogression of thoracic tumors after chest radiotherapy might become a common phenomenon. It is important for us to identify pseudoprogression based on patient’s general status, radiological changes, and laboratory tests. Frontiers Media S.A. 2023-07-28 /pmc/articles/PMC10419187/ /pubmed/37576884 http://dx.doi.org/10.3389/fonc.2023.1021253 Text en Copyright © 2023 Xiang, Tang, Wang, Wang and Bi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xiang, Yongbo
Tang, Wei
Wang, Jianyang
Wang, Zhijie
Bi, Nan
Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
title Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
title_full Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
title_fullStr Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
title_full_unstemmed Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
title_short Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
title_sort pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419187/
https://www.ncbi.nlm.nih.gov/pubmed/37576884
http://dx.doi.org/10.3389/fonc.2023.1021253
work_keys_str_mv AT xiangyongbo pseudoprogressionofthoracictumorafterradiotherapyintheeraofimmunotherapyacaseseries
AT tangwei pseudoprogressionofthoracictumorafterradiotherapyintheeraofimmunotherapyacaseseries
AT wangjianyang pseudoprogressionofthoracictumorafterradiotherapyintheeraofimmunotherapyacaseseries
AT wangzhijie pseudoprogressionofthoracictumorafterradiotherapyintheeraofimmunotherapyacaseseries
AT binan pseudoprogressionofthoracictumorafterradiotherapyintheeraofimmunotherapyacaseseries